NovoCure’s $655M Revenue Signals a Shift in Direct-to-Patient Cancer Care

For healthcare systems and providers, the divergence between Amgen’s wholesale distribution and NovoCure’s direct-to-patient model is more than an investment thesis—it’s a blueprint for the future of care delivery. NovoCure’s wearable Optune Gio bypasses middlemen, placing the technology directly in patients’ hands and generating recurring revenue through device fees. This model promises greater patient engagement and real-world data collection, but also demands robust payer partnerships and clinical outcome validation. Meanwhile, Amgen’s reliance on three massive wholesalers exposes the pharma ecosystem to concentration risk and margin compression. Understanding these operational paradigms is critical for hospital networks, payers, and digital health strategists navigating the next wave of value-based care.

The 2026 healthcare investment landscape presents a stark contrast between two business models: Amgen, a pharmaceutical behemoth generating $36.8 billion in 2025 revenue, and NovoCure, a medical device innovator with $655.4 million in sales but still deeply unprofitable. This comparison, drawn from recent analysis, underscores a broader market dynamic where established cash‑flow machines compete for capital against high‑risk, high‑reward disruptors. For healthcare industry observers, the juxtaposition illuminates pivotal trends in drug distribution, oncology treatment paradigms, and investor appetite for innovation versus stability.

“

In fiscal 2025, revenue grew 10.1% year‑over‑year to nearly $36.8 billion, driven by blockbuster therapies across cardiovascular disease, obesity, and oncology.

Amgen’s scale is formidable. In fiscal 2025, revenue grew 10.1% year‑over‑year to nearly $36.8 billion, driven by blockbuster therapies across cardiovascular disease, obesity, and oncology. Net income reached $7.7 billion, yielding a net margin above 20%. The company generated $8.1 billion in free cash flow, a figure that dwarfs NovoCure’s entire revenue base. However, Amgen’s financial profile carries material risk factors. Its customer base is extremely concentrated: three pharmaceutical wholesalers—McKesson, Cencora, and Cardinal Health—account for a dominant share of sales. This dependence exposes Amgen to pricing pressure, channel inventory shifts, or consolidation within the distribution tier. Moreover, a debt‑to‑equity ratio of 6.3x signals aggressive leverage, a legacy of past acquisitions. While the ample free cash flow comfortably services this debt, the capital structure limits strategic flexibility and amplifies downside sensitivity in a rising‑rate environment.

NovoCure, by contrast, operates a unique direct‑to‑patient model. Its wearable Optune Gio device delivers tumor‑treating fields (TTFields) for glioblastoma and other cancers, bypassing traditional wholesalers entirely. In fiscal 2025, revenue rose 8.3% to $655.4 million, demonstrating growing clinical adoption and expanding reimbursement coverage. Yet the company remains in the red, with a net loss of $136.2 million. The direct‑to‑patient approach fosters close patient relationships and recurring monthly device fees, but the cost of scaling manufacturing, clinical trials, and global commercial infrastructure continues to weigh on profitability. The model’s success hinges on payer negotiations and clinical guideline endorsements; any setback in reimbursement policy or trial results could stall the already fragile path to breakeven.